Title of article
Genetic evidence for a tumor suppressor role of HIF-2α
Author/Authors
Acker، نويسنده , , Till and Diez-Juan، نويسنده , , Antonio and Aragones، نويسنده , , Julian and Tjwa، نويسنده , , Marc and Brusselmans، نويسنده , , Koen and Moons، نويسنده , , Lieve and Fukumura، نويسنده , , Dai and Moreno-Murciano، نويسنده , , Maria Paz and Herbert، نويسنده , , Jean-Marc and Burger، نويسنده , , Angelika and Riedel، نويسنده , , Johanna and Elvert، نويسنده , , Gerd and Flamme، نويسنده , , Ingo and Maxwell، نويسنده , , Patrick H. and Collen، نويسنده , , Désiré and Dewerchin، نويسنده , , Mieke and Jain، نويسنده , , Rakesh K. and Plate، نويسنده , , Karl H. and Carmeliet، نويسنده , , Peter، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2005
Pages
11
From page
131
To page
141
Abstract
Summary
poxia-inducible transcription factors HIF-1α and HIF-2α are activated in hypoxic tumor regions. However, their role in tumorigenesis remains controversial, as tumor growth promoter and suppressor activities have been ascribed to HIF-1α, while the role of HIF-2α remains largely unknown. Here, we show that overexpression of HIF-2α in rat glioma tumors enhances angiogenesis but reduces growth of these tumors, in part by increasing tumor cell apoptosis. Moreover, siRNA knockdown of HIF-2α reduced apoptosis in hypoxic human malignant glioblastoma cells. Furthermore, inhibition of HIF by overexpression of a dominant-negative HIF transgene in glioma cells or HIF-2α deficiency in teratomas reduced vascularization but accelerated growth of these tumor types. These findings urge careful consideration of using HIF inhibitors as cancer therapeutic strategies.
Journal title
Cancer Cell
Serial Year
2005
Journal title
Cancer Cell
Record number
1335672
Link To Document